ArticleBMC cancer2026
Role of glutathione disulfide reductase in colorectal cancer: a tumor suppressor.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlutathione-disulfide reductase (GSR) was responsible for maintaining the supply of reduced glutathione, and was found to be abnormally expressed in a variety of cancers. There was an incomplete understanding regarding the roles of GSR in colorectal cancer (CRC) today.
methodsWe used colorectal cancer tissues and cell lines to detect the function of GSR in CRC. We also used bioinformatics to analyze the related pathways of GSR in colorectal cancer.
resultsGSR mRNA was down-regulated in CRC (p < 0.05). The expression of GSR mRNA with T3 and T4 patients was lower than that with T1 and T2 patients, with M1 patients was lower than that with M0 patients, with N1 and N2 patients was lower than that with N0 stage patients, with stage 3 and stage 4 patients was lower than that with stage1 and stage 2 patients (p < 0.05). Overall survival (OS), disease-specific survival (DSS), progression survival (PFS), post-progression survival (PPS) and recurrence-free survival (RFS) time for patients with high expression of GSR was higher than that for patients with low GSR expression (p < 0.05). The expression of p-p38 MAPK and p-ERK increased in GSR knockdown cells, while the expression of p-Nrf2, KEAP1, p-PI3K and p-Akt decreased. Consistent with alterations in the MAPK/ERK signaling pathway, cells with GSR knockdown exhibited significantly enhanced proliferative, migratory, and invasive capabilities, along with increased ROS production (all p < 0.001), while showing a reduced apoptosis rate (p < 0.001). Furthermore, both re-expression of GSR and treatment with an ERK inhibitor effectively reversed the phenotypic and molecular changes induced by GSR knockdown.
conclusionThe expression of GSR was closely related to the development of colorectal cancer. GSR was low expressed and played a tumor-suppressive role through inhibiting the production of ROS, and the activation of p38 MAPK/ERK pathways in CRC. GSR has the potential to become a potential biomarker for the diagnosis and treatment of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.